

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug platforms</b>			
Sortase-catalyzed modification to increase stability of therapeutic proteins	<p><i>In vitro</i> and mouse studies suggest that sortase-mediated pegylation and circularization could improve the stability of recombinant protein therapeutics. Sortase-mediated, site-specific pegylation of the C-terminus of interferon-<math>\alpha_2</math> (IFNA2; IFN-<math>\alpha_2</math>) or G-CSF (CSF3) led to an increased half-life in mice, whereas <i>in vitro</i> biological potency was similar to that in non-pegylated controls. Sortase-mediated pegylation and circularization of IFNA2 led to a greater thermal stability <i>in vitro</i> and a greater circulating half-life in mice than an unmodified precursor control. Next steps could include extending the method to modify the N-terminus of therapeutic proteins.</p> <p><b>SciBX 4(7); doi:10.1038/scibx.2011.207</b>            Published online Feb. 17, 2011</p>	Patent application filed; available for licensing	<p>Popp, M.W. <i>et al.</i>  <i>Proc. Natl. Acad. Sci. USA</i>;            published online Jan. 31, 2011;            doi:10.1073/pnas.1016863108</p> <p><b>Contact:</b> Hidde L. Ploegh,            Whitehead Institute for            Biomedical Research,            Cambridge, Mass.            e-mail:  <a href="mailto:ploegh@wi.mit.edu">ploegh@wi.mit.edu</a></p>